Adagio Therapeutics, Inc. is a clinical-stage a biotechnology company developing best-in-class antibodies that can broadly neutralize SARS-CoV-2, SARS-CoV-1 and additional pre-emergent coronaviruses. Our candidates are optimized using Adimab’s industry-leading antibody engineering capabilities and are designed to provide patients and clinicians with an unsurpassed combination of potency, breadth, durable protection (via half-life extension), manufacturability, tolerability, and affordability. Our portfolio of SARS-CoV-2 antibodies includes multiple, non-competing antibodies with distinct binding epitopes. Pre-clinical data show that our lead antibody ADG20 matches or exceeds the potency and coverage of other clinical SARS-CoV-2 antibody programs. We plan to advance ADG20 aggressively through global clinical trials for both the prevention and treatment of symptomatic COVID-19 and anticipate data from both prevention and treatment clinical trials in 2021. Adagio has secured manufacturing capacity for the production of ADG20 with third party contract manufacturers through the completion of clinical trials and, if approved by regulatory authorities, through initial commercial launch. For more information: www.adagiotx.com
Location: United States, Massachusetts, Waltham
Employees: 51-200
Total raised: $466M
Founded date: 2020
Investors 8
Funding Rounds 3
| Date | Series | Amount | Investors |
| 19.04.2021 | Series C | $336M | - |
| 10.11.2020 | Series B | $80M | - |
| 16.07.2020 | Series A | $50M | - |
Mentions in press and media 13
| Date | Title | Description |
| 06.08.2021 | Adagio raises $300 million in IPO, looks to advance Covid-19 antibody therapy | Adagio Therapeutics, a Waltham startup advancing COVID-19 antibody treatments, is going public Friday just over one year after it was founded. The company raised nearly $310 million by selling 18,200,000 shares for $17 each, in the middle o... |
| 20.04.2021 | Adagio Therapeutics Announces $336M Series C | WALTHAM, MA, Adagio Therapeutics, a biotechnology company, has completed a $336 million Series C financing led by RA Capital Management. >> Click here for more funding data on Adagio Therapeutics >> To export Adagio Therapeu... |
| 19.04.2021 | Adagio raises $336 million to advance Covid-19 antibody treatment | Waltham-based Adagio Therapeutics announced on Monday that it has raised $336 million in new funding to rapidly advance its Covid-19 antibody treatment, which aims to treat and prevent the disease and all of its known variants. Last week th... |
| 19.04.2021 | Adagio Therapeutics Announces $336 Million Series C Financing to Support Rapid Advancement of Novel ADG20 Antibody for the Treatment and Prevention of COVID-19 | - |
| 19.04.2021 | Adagio Therapeutics Announces $336 Million Series C Financing to Support Rapid Advancement of Novel ADG20 Antibody for the Treatment and Prevention of COVID-19 | Adagio Therapeutics, Inc., a biotechnology company developing best-in-class antibodies to broadly neutralize coronaviruses, today announced the completion of a $336 million Series C financing led by RA Capital Management, with participation... |
| 19.04.2021 | Adagio Therapeutics Raises $336M in Series C Financing | Adagio Therapeutics, Inc., a Waltham, Mass. – based biotechnology company developing antibodies to broadly neutralize coronaviruses, completed a $336m Series C financing. The round was led by RA Capital Management, with participation from n... |
| 19.04.2021 | Adagio raises a monster $336M round for bespoke COVID-19 drug battle | Adagio Therapeutics has nabbed a massive $336 million series C from a who’s who of investors as it more than triples its previous funding drive last year. article Make the Right Move at Every Step of the Drug Commercialization Process Learn... |
| 10.11.2020 | Adagio Therapeutics Raises $80M Series B Round to Further Advance Best-In-Class Antibodies for Coronavirus Treatment and Prevention | - |
| 10.11.2020 | Adagio Therapeutics Raises $80M in Series B Funding | Adagio Therapeutics, Inc., a Waltham, Mass.-based company developing antibodies that broadly neutralize SARS-CoV-2, SARS-CoV-1, and additional potentially emergent coronaviruses, closed an $80m Series B financing. The round was led by GV, w... |
| 10.11.2020 | Adagio Therapeutics Raises $80M Series B | WALTHAM, Mass.--(BUSINESS WIRE)--Adagio Therapeutics, Inc., a company developing best-in-class antibodies that broadly neutralize SARS-CoV-2, SARS-CoV-1, and additional potentially emergent coronaviruses, today announced the closing of an $... |
Show more